|
|
|
|
| LEADER |
00000cam a2200000 4500 |
| 001 |
ocn870245941 |
| 003 |
OCoLC |
| 005 |
20240623213015.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
140208s2013 sz o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d YDXCP
|d OCLCQ
|d AU@
|d OCLCQ
|d REDDC
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 019 |
|
|
|a 900687006
|
| 020 |
|
|
|a 9789240691100
|
| 020 |
|
|
|a 9240691103
|
| 035 |
|
|
|a (OCoLC)870245941
|z (OCoLC)900687006
|
| 050 |
|
4 |
|a RS189
|
| 049 |
|
|
|a HCDD
|
| 100 |
1 |
|
|a Organization, World Health.
|
| 245 |
1 |
0 |
|a WHO Drug Information Vol. 27 No. 1 2013.
|
| 260 |
|
|
|a Geneva :
|b World Health Organization,
|c 2013.
|
| 300 |
|
|
|a 1 online resource (95 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Cover; Contents; Access to Blood Products; Access to safe and effective blood products in low and middle income countries; Current Topics; Mechanism to combat substandard/spurious/falsely-labelled/falsified/counterfeit medical products; Reference; Speeding up access to quality medicines in Africa; Reference; PQM technical support for prequalification of medicines; Reference; International Generic Drug Regulator's Pilot Project; Reference; Safety and Efficacy Issues; Tolvaptan: risk of liver injury; Reference; Roflumilast: risk of suicidal behaviour; Reference.
|
| 505 |
8 |
|
|a Sodium picosulfate/magnesium citrate: convulsionsReferences; Risperidone and rhabdomyolysis; References; Docetaxel: serious respiratory-related adverse reactions; References; Zolpidem: impaired activity; Reference; Combination treatment with telaprevir, peginterferon alfa and ribavirin: serious skin reactions; Reference; Dabigatran etexilate mesylate: not for patients with mechanical prosthetic heart valves; References; Sodium oxybate with alcohol or drugs: respiratory depression; Reference; Statins: risk of increased blood sugar levels and diabetes; Reference.
|
| 505 |
8 |
|
|a Immunomodulatory medicines: progressive multifocal leuko-encephalopathyReferences; Thyroxine and fractures; References; Oral bowel cleansing products: serious electrolyte disturbances; Reference; Combined contraceptives: venous and arterial thromboembolism; Reference; Fibrin sealant spray: gas embolism; Reference; Corticosteroids: musculoskeletal adverse events; References; Regulatory Action and News; Herbal medicines: strengthening assessment methodology and improved communication; Reference; Advanced therapies: incentives and strengthened interaction; Reference.
|
| 505 |
8 |
|
|a Methodologies in pharmacovigilance and pharmacoepidemiologyReference; Nicotinic acid/laropiprant: suspension recommended; Reference; Bevacizumab approved for meta-static colorectal cancer; Reference; Mercury free healthcare; Reference; Ocriplasmin: approved for vitreo-macular traction; Reference; India: clinical trial conditions amended; Reference; eSubmission Gateway release II and eSubmission web client; Reference; Deferasirox approved for nontransfusion-dependent thalassaemia; Reference; Pomalidomide approved for advanced multiple myeloma; Reference.
|
| 505 |
8 |
|
|a Nalmefene approved for reduction of alcohol consumptionReference; Mipomersen sodium and lomitapide approved for inherited cholesterol disorder; Reference; Memantine: Imatinib mesilate: marketing authorization application withdrawal; Reference; Imatinib mesilate: marketing authorizaation application withdrawal; Reference; Recent Publications, Information and Events; WHO/WIPO/WTO: health innovation and access to medicines; Reference; EPN study: availability and pricing of children's medicines in Ghana; Reference; IOM report on substandard and falsified medicines; Reference.
|
| 500 |
|
|
|a HIFA: Information for healthcare providers.
|
| 520 |
|
|
|a WHO Drug Information communicates pharmaceutical information that is either developed and issued by WHO or transmitted to WHO by research and regulatory agencies throughout the World. The journal also includes regular presentations of newly proposed and recommended International Nonproprietary Names (INN) for Pharmaceuticals Substances. This volume contains the recommended INN List No. 69.
|
| 650 |
|
0 |
|a Drugs
|x Standards
|v Periodicals.
|
| 650 |
|
0 |
|a Pharmaceutical industry
|v Periodicals.
|
| 650 |
|
0 |
|a Pharmaceutical Preparations
|x Standards
|v Periodicals.
|
| 650 |
|
7 |
|a Drugs
|x Standards
|2 fast
|
| 650 |
|
7 |
|a Pharmaceutical industry
|2 fast
|
| 655 |
|
7 |
|a Periodicals
|2 fast
|
| 758 |
|
|
|i has work:
|a WHO Drug Information Vol. 27 No. 1 2013 (Text)
|1 https://id.oclc.org/worldcat/entity/E39PD3gRFwwPYpfT3Dqm9TVbv3
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Organization, World Health.
|t WHO Drug Information Vol. 27 No. 1 2013.
|d Geneva : World Health Organization, ©2013
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=1611999
|y Click for online access
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|